NCT04906434: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 50 | RoW | 60mg ABSK-011capsule, FGFR4 inhibitor, 120mg ABSK-011capsule, 180mg ABSK-011capsule, 240mg ABSK-011capsule, 320 mg ABSK-011capsule, 400mg ABSK-011capsule | Abbisko Therapeutics Co, Ltd | Advanced Liver Cancer | 12/23 | 08/25 | | |
NCT06306872: A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules |
|
|
| Recruiting | 1 | 73 | RoW | Sequence A ABSK-011, Sequence B ABSK-011 | Abbisko Therapeutics Co, Ltd | Healthy Subjects | 12/24 | 12/24 | | |
